Canagliflozin (Invokana): How It Works, Doses, Benefits, and Risks

What Is Canagliflozin and How Does It Work?

Canagliflozin belongs to the SGLT2 inhibitor class and works by blocking a transporter in the proximal tubule of the kidney that normally reclaims about 90% of filtered glucose back into the bloodstream. By blocking that transporter, the drug forces the kidneys to excrete roughly 70, 90 grams of glucose per day in urine, which lowers blood sugar without requiring insulin secretion [1].

The FDA first approved canagliflozin in March 2013 under the brand name Invokana, making it the first SGLT2 inhibitor to reach the U.S. market [2]. It was subsequently approved by the FDA in September 2019 specifically for the reduction of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria greater than 300 mg/day [2].

Because the glucose-lowering mechanism is entirely independent of insulin, canagliflozin works at any stage of type 2 diabetes and can be combined with virtually every other antidiabetic drug class, including metformin, sulfonylureas such as glipizide, thiazolidinediones such as pioglitazone, DPP-4 inhibitors, GLP-1 receptor agonists, and insulin [3]. The osmotic diuresis and mild natriuresis that accompany glucosuria also lower blood pressure by approximately 3 to 5 mmHg systolic without reflex tachycardia, an added benefit in patients who are already hypertensive [4].

Approved Indications and FDA Labeling

The FDA label for Invokana covers two distinct clinical scenarios: glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise, and cardiovascular risk reduction in adults with type 2 diabetes who also have established cardiovascular disease [2]. The 2019 label expansion added the nephropathy indication based on the CREDENCE trial.

Canagliflozin is not approved for type 1 diabetes or for patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² for glycemic purposes, though the CREDENCE indication extends use down to eGFR 30 for renal protection [2]. The American Diabetes Association's 2024 Standards of Care specify SGLT2 inhibitors with proven benefit as preferred add-on therapy for patients with type 2 diabetes and chronic kidney disease (CKD), heart failure with reduced ejection fraction, or atherosclerotic cardiovascular disease, regardless of HbA1c [5].

Quoting directly from the 2024 ADA Standards: "In patients with type 2 diabetes and CKD, use of an SGLT2 inhibitor with demonstrated kidney benefit is recommended to reduce CKD progression and cardiovascular events" [5].

Dosing and Administration

The standard starting dose is 100 mg once daily taken before the first meal of the day. If additional glycemic control is needed and the patient tolerates the 100 mg dose, it may be increased to 300 mg once daily [2].

Dose adjustments depend on kidney function. For patients with eGFR 45 to 59 mL/min/1.73 m², the 300 mg dose should not be used for glycemic control; the 100 mg dose may be continued. For eGFR below 45, canagliflozin should be discontinued for glycemic indications, though it may be continued for its cardio-renal indications down to eGFR 30 [2]. Hepatic impairment does not require dose adjustment for mild or moderate cases, but use in severe hepatic impairment (Child-Pugh class C) is not recommended due to lack of data [2].

Canagliflozin is available generically in the United States and also as fixed-dose combinations: Invokamet (canagliflozin/metformin immediate release) in doses of 50/500 mg, 50/1 to 000 mg, 150/500 mg, and 150/1 to 000 mg; and Invokamet XR (canagliflozin/metformin extended release) [3].

Glycemic Efficacy: What the Trials Show

In the Phase 3 program supporting approval, canagliflozin 100 mg reduced HbA1c by approximately 0.77% versus placebo at 26 weeks, while the 300 mg dose reduced it by approximately 1.03% [6]. Fasting plasma glucose fell by 27 to 29 mg/dL at 100 mg and 36 to 38 mg/dL at 300 mg compared with placebo [6].

The DIA3008 study (N=1,450) compared canagliflozin 300 mg directly with glipizide (a sulfonylurea titrated up to 20 mg daily) over 52 weeks. Both arms achieved similar HbA1c reductions of approximately 0.82%, but canagliflozin produced a 3.7 kg mean weight loss compared with a 0.7 kg mean weight gain in the glipizide arm [7]. Hypoglycemia occurred in 3.8% of the canagliflozin group versus 34.2% in the glipizide group, a clinically meaningful difference that speaks directly to patient safety in the outpatient setting [7].

A head-to-head comparison with sitagliptin (DIA3006, N=756) over 52 weeks showed canagliflozin 300 mg produced superior HbA1c reduction (difference: -0.37%, P<0.001) and greater weight loss (-2.3 kg difference) [8].

Cardiovascular Outcomes: The CANVAS Program

The CANVAS Program pooled two trials (CANVAS and CANVAS-R, combined N=10,142) to evaluate canagliflozin in adults with type 2 diabetes at high cardiovascular risk [9]. Patients had a mean age of 63 years, mean duration of diabetes of 13.5 years, and mean HbA1c of 8.2%.

Over a median follow-up of 188 weeks, canagliflozin reduced the primary composite of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 14% compared with placebo (HR 0.86 to 95% CI 0.75, 0.97) [9]. Hospitalization for heart failure was reduced by 33% (HR 0.67 to 95% CI 0.52, 0.87) [9].

The same program documented a doubling of lower-limb amputation risk (HR 1.97 to 95% CI 1.41, 2.75), predominantly at the toe or metatarsal level [9]. This signal led the FDA to add a black-box warning, and the package insert now states canagliflozin should be avoided in patients with active foot ulcers, severe peripheral artery disease, or recurrent foot infections [2].

Subsequent analyses suggested the amputation risk may be partially explained by volume depletion and patient selection rather than a class effect, since empagliflozin and dapagliflozin did not show the same signal in EMPA-REG OUTCOME and DECLARE-TIMI 58, respectively [10]. Prescribers should conduct a thorough vascular examination of the lower extremities before initiating canagliflozin [2].

Renal Outcomes: The CREDENCE Trial

CREDENCE (N=4,401) was the first dedicated renal outcomes trial for any SGLT2 inhibitor [11]. Patients had type 2 diabetes, eGFR 30 to 90 mL/min/1.73 m², and a urinary albumin-to-creatinine ratio of 300, 5 to 000 mg/g, all on stable renin-angiotensin-aldosterone system blockade. The trial was stopped early at a median follow-up of 2.62 years because canagliflozin crossed the pre-specified efficacy boundary.

Canagliflozin 100 mg once daily reduced the primary composite endpoint (end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death) by 30% (HR 0.70 to 95% CI 0.59, 0.82, P<0.001) [11]. The number needed to treat to prevent one primary endpoint event over 2.5 years was 22 [11].

The 2022 KDIGO Clinical Practice Guideline for Diabetes Management in CKD recommends canagliflozin (or another proven SGLT2 inhibitor) as first-line add-on therapy in patients with type 2 diabetes and CKD with eGFR at or above 20 mL/min/1.73 m², regardless of whether glycemic targets have been met [12]. This represents a shift in thinking: canagliflozin is now considered an organ-protective drug first and a glucose-lowering drug second in this population.

Side Effects and Safety Profile

The most common side effects with canagliflozin reflect its mechanism. Genital mycotic infections (yeast infections) occur in approximately 10.4% of women and 4.2% of men, compared with 3.2% and 0.9% respectively in placebo groups, owing to the high glucose concentration in urine [13]. These are generally mild and respond to standard antifungal treatment, though recurrent cases may warrant drug discontinuation.

Urinary tract infections occur at a modestly higher rate than placebo in some trials, though pooled analyses have not shown a consistent statistically significant difference [13]. Volume depletion (dizziness, orthostatic hypotension) occurs in approximately 1.5 to 2.4% of patients, particularly in those also taking loop diuretics or who are elderly with reduced fluid intake [2].

Diabetic ketoacidosis (DKA) is a rare but serious event, occurring even at near-normal blood glucose levels (euglycemic DKA). The FDA added a warning in 2015 [14]. Risk factors include prolonged fasting, significant caloric restriction, alcohol use, surgery, and off-label use in type 1 diabetes. Canagliflozin should be held 3 days before elective surgery per most institutional protocols.

Bone fractures were noted at a higher rate in the CANVAS Program (HR 1.26 for fractures at 12 weeks) [9]. A reduction in hip bone mineral density of approximately 0.9 to 1.2% at 12 months was observed in dedicated bone substudy data [15]. The mechanism may involve phosphate retention and FGF-23 elevation. Patients with established osteoporosis or high fracture risk warrant individualized assessment.

Hyperkalemia, a concern with any agent that reduces GFR acutely, can occur particularly when canagliflozin is combined with potassium-sparing agents or in patients with advanced CKD [2].

Comparing Canagliflozin With Other Common Diabetes Drugs

Canagliflozin vs. Metformin

Metformin remains the most prescribed oral diabetes drug in the United States and is recommended as initial therapy by the ADA for most patients with type 2 diabetes who can tolerate it [5]. It lowers HbA1c by 1.0 to 1.5% and is weight-neutral to modestly weight-reducing, with a favorable safety profile and very low cost [5]. Canagliflozin is typically added to metformin when glycemic targets are not met or when a patient has high cardiovascular or renal risk that warrants the proven benefits of an SGLT2 inhibitor. The Invokamet combination tablet provides both agents in a single pill for adherence convenience.

Metformin does not carry the cardiovascular or renal outcomes data that canagliflozin does. The UK Prospective Diabetes Study (UKPDS 34, N=1,704) showed metformin reduced any diabetes-related endpoint by 32% (P<0.002) in overweight patients, but this trial predates modern cardiovascular outcome methodology and did not assess heart failure or kidney failure as primary endpoints [16].

Canagliflozin vs. Glipizide (Sulfonylurea)

Sulfonylureas such as glipizide stimulate insulin secretion from pancreatic beta cells regardless of blood glucose level, which explains their relatively high hypoglycemia rate. In DIA3008, hypoglycemia was 9 times more common with glipizide titrated to maximum than with canagliflozin at 300 mg [7]. Glipizide is associated with weight gain of approximately 1 to 2 kg over one year, while canagliflozin produces weight loss [7]. Sulfonylureas are substantially cheaper, which matters in cost-sensitive prescribing, but the safety difference is meaningful for patients who drive, operate machinery, or live alone.

No dedicated cardiovascular outcomes trial has shown sulfonylureas reduce MACE. A meta-analysis published in The Lancet Diabetes and Endocrinology (N=approximately 1.5 million patient-years across observational studies) found sulfonylureas associated with higher all-cause mortality compared with SGLT2 inhibitors [17].

Canagliflozin vs. Pioglitazone (Actos)

Pioglitazone, a thiazolidinedione, activates PPAR-gamma receptors to improve insulin sensitivity in muscle, liver, and adipose tissue. The PROactive trial (N=5,238) showed pioglitazone reduced the secondary composite of cardiovascular death, MI, and stroke by 16% (HR 0.84, P=0.027), but the primary composite endpoint was not statistically significant [18]. Pioglitazone causes fluid retention and is contraindicated in heart failure (NYHA Class III and IV). Weight gain of 3 to 5 kg is common. Canagliflozin, by contrast, reduces both weight and fluid volume, making it the preferable choice in patients with heart failure or obesity.

Pioglitazone has a lower acquisition cost than branded canagliflozin and remains useful in patients who need insulin sensitization without the amputation or genital infection risks associated with SGLT2 inhibition.

Canagliflozin vs. Empagliflozin (Jardiance)

Both are SGLT2 inhibitors with cardiovascular and renal outcomes data, and they share a similar mechanism. The head-to-head comparison comes down to trial populations and specific outcomes.

EMPA-REG OUTCOME (N=7,020) showed empagliflozin reduced cardiovascular death by 38% (HR 0.62 to 95% CI 0.49, 0.77) and hospitalization for heart failure by 35% (HR 0.65 to 95% CI 0.50, 0.85) [10]. The EMPEROR-Reduced trial (N=3,730) extended empagliflozin's heart failure indication to patients with or without diabetes [19].

Canagliflozin's CREDENCE trial showed the strongest kidney-specific evidence for any SGLT2 inhibitor at the time of publication, with a 34% reduction in end-stage kidney disease alone (HR 0.68, P=0.002) [11]. However, the EMPA-KIDNEY trial (N=6,609) subsequently showed empagliflozin also reduced CKD progression by 28% (HR 0.72 to 95% CI 0.64, 0.82) across a broader range of kidney disease including non-diabetic CKD [20].

Empagliflozin does not carry the amputation black-box warning that canagliflozin does. For patients with peripheral vascular disease or a history of foot problems, many clinicians prefer empagliflozin or dapagliflozin on that basis alone. For patients without those risk factors, the two drugs are broadly interchangeable at the class level, and formulary availability often determines the choice.

Who Should and Should Not Take Canagliflozin

Canagliflozin is a strong candidate for adults with type 2 diabetes who also have any of the following: established atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, diabetic nephropathy with albuminuria above 300 mg/day, or obesity requiring weight management support.

Patients who should avoid canagliflozin include those with eGFR below 30 mL/min/1.73 m² (for glycemic use), type 1 diabetes (not approved, high DKA risk), active foot ulcers or severe peripheral artery disease, recurrent genital mycotic infections unresponsive to treatment, or a history of SGLT2 inhibitor-associated DKA.

The 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Algorithm recommends adding an SGLT2 inhibitor with outcomes data when a patient with atherosclerotic cardiovascular disease, CKD, or heart failure does not achieve glycemic targets on metformin alone, placing canagliflozin among the preferred second-line agents in those patient groups [21].

Monitoring Parameters While on Canagliflozin

Before starting canagliflozin, clinicians should obtain a baseline eGFR, urine albumin-to-creatinine ratio, HbA1c, blood pressure, and a clinical exam of the lower extremities including assessment for peripheral artery disease [2]. An eGFR recheck at 2 to 4 weeks after initiation is reasonable to detect any acute hemodynamic decline, which is typically transient and not a reason to stop the drug unless eGFR falls below the threshold for the prescribed indication.

During ongoing therapy, HbA1c should be checked every 3 months until stable, then every 6 months [5]. Annual foot exams are standard of care for all patients with diabetes and take on added importance given the amputation signal [5]. Electrolytes, particularly potassium in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics, should be monitored periodically [2].

Patients should be counseled to hold canagliflozin during any illness causing significant dehydration, fasting greater than 12 hours before a procedure, or hospitalization for any major surgical event, to reduce the risk of euglycemic DKA and volume depletion [14].